NCI-H69VCR/R

Drug-resistance studies

Human small cell lung cancer, drug-resistant

NCI-H69 VCR/R has been derived from the parent small cell lung cancer line NCI-H69 (Sigma Catalogue number. 91091802) It is recommended to culture cells without drug upon resuscitation; add vincristine once growth is fully established. The Y chromosome could not be detected in this cell line by short tandem repeat (STR)-PCR analysis when tested at ECACC. It is a known phenomenon that due to the increased genetic instability of cancer cell lines the Y chromosome can be rearranged or lost resulting in lack of detection. The cell line is identical to the source provided by the depositor based on the STR-PCR analysis.

STR-PCR Data: Amelogenin: X
CSF1PO: 12
D13S317: 12
D16S539: 11
D5S818: 11
D7S820: 9
THO1: 8,9
TPOX: 10
vWA: 16,17

Maintain cultures between 3-9x 100,000 cells/ml; 5% CO₂; 37ºC. Resuscitate in drug-free medium, add after growth has been established.

RPMI 1640 + 2mM Glutamine + 2.0 μg/ml vincristine + 10% Foetal Bovine Serum (FBS).

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.